(London Reuters) Chinese Pharmaceutical CEO Yu Xuefeng said that the company's experimental coronary vaccine using messenger ribonucleic acid (MRNA) technology can be comparable to Moderna and Pfizer-Biontech (PFIZER-BIONTECH vaccine.
According to Reuters, Yu Xuefeng said on Friday (February 3) that because Modner and Pfizer-Biontech vaccine was not approved in China, it was not possible to directly study with the Kangxino vaccine, but according to the announced, it has been announced.Data, he believes that Kangxino's products are as good as the MRNA vaccine that has been listed.
Kangshino issued an announcement on January 5 that the first MRNA vaccine CS-2034 has begun to try production and achieve positive progress.
For whether the Chinese government is more inclined to develop a domestic MRNA vaccine, Yu Xuefeng said that there are currently not many related public information, but from a technical point of view, as long as any product meets the regulatory requirements, there is no reason not to let them enter the market.
Yu Xuefeng also said that Kangxino is currently discussing with the Chinese regulatory agency on the later research plan of CS-20134 and will conduct tests this year.If the vaccine is approved, Kangxino will try to reduce its manufacturing and launch costs.Compared with Pfizer's vaccine that sells for about $ 120 per dose and a dose of about $ 120 (S $ 159), the Cumino vaccine is definitely cheaper.
After the relaxation of crown disease prevention restrictions in December 2022, China has not yet approved the use of MRNA vaccines from abroad, and has not approved domestic vaccines using the technology.
There are more than 10 companies in China's layout of MRNA vaccines, and at least eight MRNA vaccines have entered the clinical trial stage.
